ATEM (Alvesco Non-interventional Study)

Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01147224

Acronym

ATEM

Enrollment

400

Registered

2010-06-22

Start date

2010-03-31

Completion date

2011-08-31

Last updated

2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Asthma

Keywords

Asthma, Allergy, Ciclesonide, Alvesco, Inhaled steroids

Brief summary

The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .

Interventions

DRUGAlvesco

This is an observational study. Therefore, the physician decides about dosage according to individual needs.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Main Inclusion Criteria: * Asthma with or without allergic components Main

Exclusion criteria

* Hypersensitive to compounds of Alvesco * Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3

Design outcomes

Primary

Measure	Time frame	Description
Treatment success with Alvesco	after 3 months	Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire

Secondary

Measure	Time frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	after 3 months

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026